Press Releases

Date Title and Summary Additional Formats
Toggle Summary ArQule Announces Top-Line Results of Phase 3 Clinical Study of Tivantinib in Hepatocellular Carcinoma in Japan
BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today reported that its partner, Kyowa Hakko Kirin, announced top-line results of the JET-HCC Phase 3 trial of tivantinib in Japan , and that the trial did not meet its primary endpoint of progression free survival (PFS).
View HTML
Toggle Summary ArQule Reports Fourth Quarter and Full Year 2016 Financial Results
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for the fourth quarter and full year of 2016. For the quarter ended December 31, 2016 , the Company reported a net loss of $6,820,000 or $0.10 per
View HTML
Toggle Summary ArQule To Report Fourth Quarter and Year End 2016 Financial Results On March 7, 2017
BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule , Inc. (Nasdaq: ARQL) today announced it will report financial results for the fourth quarter and full year 2016 before the market opens on Tuesday, March 7, 2017 . The Company will hold a conference call and webcast on the same day at 9:00 a.m.
View HTML
Toggle Summary Daiichi Sankyo and ArQule Announce the Completion of the METIV-HCC Phase 3 Study of Tivantinib in Second-Line Treatment of MET-Overexpressing Hepatocellular Carcinoma
ArQule to host investor conference call on February 17, 2017 at 8:30 A.M. ET BURLINGTON, Mass. , TOKYO , MUNICH, & PARSIPPANY, N.J. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo today announced that the METIV-HCC phase 3 study of tivantinib in hepatocellular carcinoma (HCC) did
View HTML
Toggle Summary ArQule to Present at The Leerink Partners 6th Annual Global Healthcare Conference on February 15, 2017
BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci , Chief Executive Officer, and Dr. Brian Schwartz , Chief Medical Officer and Head of Research and Development, will present at The Leerink Partners 6 th Annual Global Healthcare Conference on
View HTML
Toggle Summary Data on Proprietary BTK Inhibitor, ARQ 531, Demonstrating Inhibition of Wild Type and C481S Mutant BTK and Superiority to Ibrutinib in TCL1 Mouse Model Presented at the American Society of Hematology Annual Meeting
ARQ 531 demonstrates best-in-class potential as a reversible, non-covalent BTK inhibitor BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data was presented on Bruton's tyrosine kinase (BTK) inhibitor, ARQ 531, in a poster presentation by The Ohio
View HTML
Toggle Summary Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell Disease Presented at the American Society of Hematology Annual Meeting
The study supports further exploration of ARQ 092 in sickle cell disease BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data was presented on its proprietary AKT inhibitor, ARQ 092, in an oral presentation by the University of Illinois College of
View HTML
Toggle Summary ArQule Reports Third Quarter 2016 Financial Results
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule , Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2016. For the quarter ended September 30, 2016 , the Company reported a net loss of $5,817,000 or $0.08 per share,
View HTML
Toggle Summary Advancements in ArQule's Proprietary Pipeline to be Highlighted at the 2016 American Society of Hematology Annual Meeting
BTK inhibitor, ARQ 531, potently inhibits wild type and C481S mutant BTK and is superior to ibrutinib in TCL1 mouse model for CLL AKT inhibitor, ARQ 092, has potential to treat Sickle Cell Disease BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule , Inc. (Nasdaq: ARQL) today announced that preclinical
View HTML
Toggle Summary ArQule To Report Third Quarter 2016 Financial Results On November 7, 2016
BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter 2016 before the market opens on Monday, November 7, 2016 . The Company will hold a conference call and webcast on the same day at 9:00 a.m.
View HTML

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300

These archived presentations and related materials are provided for reference by ArQule, Inc. Information contained in the materials was current only as of the date of the event. ArQule, Inc. does not update or delete outdated information contained in these materials, and it expressly disclaims any obligation to do so. The materials are property of ArQule, Inc. and any use, dissemination or republication of the files is prohibited without the express written consent of ArQule, Inc.